Table 2. Patient mutation status and clinical information.

Patient	Mutation	Clinical History
1	V600EBRAF	Patient made drastic improvement under dabrafenib (BRAF inhibitor) treatment. Bloods were collected daily during the first week treatment.
2	V600EBRAF	Patient responded to dabrafenib and trametinib (MEK-inhibitor) for 4 months before disease progression.
3	V600EBRAF	Patient did not respond to MK3475 (PD-1 inhibitor) and continued to deteriorate clinically.
4	V600KBRAF	All extracranial lesions responded to MK3475 but the intracranial lesions continued to progress. Treatment was switched to ipilimumab (anti-CTLA4 antibody).
5	V600EBRAF	Patient was enrolled in the CheckMate 067 trial (nivolumab PD-1 inhibitor versus ipilimumab versus combination of the two) and responded to the treatment well.
6	Q61HNRAS	Patient was given ipilimumab and responded well with significant improvement.